@article{494d9927321740aeaeabb008a38f0bd2,
title = "Persicamidines—Unprecedented Sesquarterpenoids with Potent Antiviral Bioactivity against Coronaviruses",
abstract = "A new family of highly unusual sesquarterpenoids (persicamidines A–E) exhibiting significant antiviral activity was isolated from a newly discovered actinobacterial strain, Kibdelosporangium persicum sp. nov., collected from a hot desert in Iran. Extensive NMR analysis unraveled a hexacyclic terpenoid molecule with a modified sugar moiety on one side and a highly unusual isourea moiety fused to the terpenoid structure. The structures of the five analogues differed only in the aminoalkyl side chain attached to the isourea moiety. Persicamidines A–E showed potent activity against hCoV-229E and SARS-CoV-2 viruses in the nanomolar range together with very good selectivity indices, making persicamidines promising as starting points for drug development.",
keywords = "Actinobacteria, Antiviral Agents, Oleandrose, Sesquarterpenes, Structure Elucidation",
author = "Lena Keller and Emilia Oueis and Amninder Kaur and Nasim Safaei and Kirsch, \{Susanne H.\} and Gunesch, \{Antonia P.\} and Sibylle Haid and Ulfert Rand and Luka {\v C}i{\v c}in-{\v S}ain and Chengzhang Fu and Joachim Wink and Thomas Pietschmann and Rolf M{\"u}ller",
note = "Funding Information: The authors acknowledge Dr. Marek Widera (Universit{\"a}tsklinikum Frankfurt am Main, Germany) for A549 cells overexpressing ACE2 and TMPRSS2 (A549-TA), Dr. Pei Yong Shi (University of Texas, Medical Branch, USA) for icSARS-CoV-2-mNeonGreen, provided via the World Reference Center for Emerging Viruses and Arboviruses (Texas, USA) and Anne K{\"u}hnel for excellent technical support in the hCoV-229E experiments. L.K., E.O., and N.S. were affiliated with the Helmholtz-Institute for Pharmaceutical Research Saarland at the time of the study, and are currently affiliated with the Hochschule Kaiserslautern at Weincampus Neustadt, Khalifa University, and TWINCORE Centre for Experimental and Clinical Infection Research, respectively. TP received funding of the Nieders{\"a}chsisches Ministerium f{\"u}r Wissenschaft und Kultur (Ministry for Science and Culture of Lower Saxony) (grant 14-76103-184 CORONA-13/20). He also received funding of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy—EXC 2155 “RESIST”—Project ID 390874280. L.C.S. was supported by the Project “Virological and immunological determinants of COVID-19 pathogenesis—lessons to get prepared for future pandemics (KA1-Co-02 ”COVIPA“)”, a grant from the Helmholtz Association's Initiative and Networking Fund. Research in Rolf M{\"u}ller's laboratory is funded by the Deutsche Forschungsgemeinschaft (DFG) and Deutsche Zentrum f{\"u}r Infektionsforschung (DZIF) Standort Hannover-Braunschweig. Open Access funding enabled and organized by Projekt DEAL. Funding Information: The authors acknowledge Dr. Marek Widera (Universit{\"a}tsklinikum Frankfurt am Main, Germany) for A549 cells overexpressing ACE2 and TMPRSS2 (A549‐TA), Dr. Pei Yong Shi (University of Texas, Medical Branch, USA) for icSARS‐CoV‐2‐mNeonGreen, provided via the World Reference Center for Emerging Viruses and Arboviruses (Texas, USA) and Anne K{\"u}hnel for excellent technical support in the hCoV‐229E experiments. L.K., E.O., and N.S. were affiliated with the Helmholtz‐Institute for Pharmaceutical Research Saarland at the time of the study, and are currently affiliated with the Hochschule Kaiserslautern at Weincampus Neustadt, Khalifa University, and TWINCORE Centre for Experimental and Clinical Infection Research, respectively. TP received funding of the Nieders{\"a}chsisches Ministerium f{\"u}r Wissenschaft und Kultur (Ministry for Science and Culture of Lower Saxony) (grant 14‐76103‐184 CORONA‐13/20). He also received funding of the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany's Excellence Strategy—EXC 2155 “RESIST”—Project ID 390874280. L.C.S. was supported by the Project “Virological and immunological determinants of COVID‐19 pathogenesis—lessons to get prepared for future pandemics (KA1‐Co‐02 ”COVIPA“)”, a grant from the Helmholtz Association's Initiative and Networking Fund. Research in Rolf M{\"u}ller's laboratory is funded by the Deutsche Forschungsgemeinschaft (DFG) and Deutsche Zentrum f{\"u}r Infektionsforschung (DZIF) Standort Hannover‐Braunschweig. Open Access funding enabled and organized by Projekt DEAL. Publisher Copyright: {\textcopyright} 2022 The Authors. Angewandte Chemie International Edition published by Wiley-VCH GmbH.",
year = "2023",
month = feb,
day = "1",
doi = "10.1002/anie.202214595",
language = "British English",
volume = "62",
journal = "Angewandte Chemie - International Edition",
issn = "1433-7851",
publisher = "John Wiley and Sons Ltd",
number = "6",
}
